Cargando…
Antipsychotic medication for women with schizophrenia spectrum disorders – CORRIGENDUM
Autores principales: | Brand, Bodyl A., Haveman, Yudith R. A., de Beer, Franciska, de Boer, Janna N., Dazzan, Paola, Sommer, Iris E. C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388308/ https://www.ncbi.nlm.nih.gov/pubmed/37161895 http://dx.doi.org/10.1017/S0033291723001344 |
Ejemplares similares
-
Antipsychotic medication for women with schizophrenia spectrum disorders
por: Brand, Bodyl A., et al.
Publicado: (2022) -
Estrogens in schizophrenia: progress, current challenges and opportunities
por: Brand, Bodyl A., et al.
Publicado: (2021) -
Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders
por: Brand, Bodyl A., et al.
Publicado: (2023) -
The Direct and Long-Term Effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Clinical Trial
por: Brand, Bodyl A, et al.
Publicado: (2023) -
Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse
por: Sommer, Iris E, et al.
Publicado: (2022)